🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 11 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 18/10/2019 | 180,25 | 180,25 | 175,38 | 176,23 | -0,84% | 2,70% | 1.122.600 |
| 17/10/2019 | 177,80 | 180,05 | 177,50 | 177,72 | +0,93% | 1,43% | 1.133.600 |
| 16/10/2019 | 175,32 | 177,20 | 173,62 | 176,09 | -0,03% | 2,04% | 749.400 |
| 15/10/2019 | 174,36 | 176,98 | 174,02 | 176,14 | +1,47% | 1,70% | 738.800 |
| 14/10/2019 | 172,32 | 175,25 | 172,32 | 173,59 | +0,68% | 1,70% | 540.600 |
| 11/10/2019 | 171,44 | 174,72 | 171,13 | 172,41 | +1,29% | 2,09% | 854.900 |
| 10/10/2019 | 168,42 | 170,37 | 167,62 | 170,22 | +0,88% | 1,63% | 765.600 |
| 09/10/2019 | 170,87 | 171,99 | 168,55 | 168,73 | -0,48% | 2,01% | 768.500 |
| 08/10/2019 | 170,47 | 171,89 | 167,60 | 169,55 | -1,45% | 2,52% | 972.100 |
| 07/10/2019 | 171,55 | 172,76 | 169,27 | 172,05 | -0,21% | 2,03% | 897.300 |
| 04/10/2019 | 170,89 | 172,92 | 170,52 | 172,42 | +1,13% | 1,40% | 873.400 |
| 03/10/2019 | 166,06 | 170,64 | 166,06 | 170,50 | +2,27% | 2,76% | 1.094.000 |
| 02/10/2019 | 167,69 | 168,52 | 165,23 | 166,71 | -0,52% | 1,96% | 1.486.100 |
| 01/10/2019 | 169,24 | 170,11 | 166,52 | 167,58 | -1,09% | 2,12% | 950.800 |
| 30/09/2019 | 169,55 | 171,29 | 167,61 | 169,42 | +1,61% | 2,17% | 1.432.300 |
| 27/09/2019 | 170,29 | 170,54 | 165,53 | 166,74 | -1,66% | 2,94% | 1.206.300 |
| 26/09/2019 | 172,05 | 172,05 | 167,43 | 169,55 | -1,14% | 2,69% | 1.593.800 |
| 25/09/2019 | 172,31 | 173,49 | 170,56 | 171,50 | -0,59% | 1,70% | 949.600 |
| 24/09/2019 | 176,32 | 177,78 | 171,03 | 172,52 | -1,91% | 3,83% | 767.400 |
| 23/09/2019 | 178,23 | 179,01 | 175,77 | 175,88 | -1,26% | 1,82% | 724.000 |
| 20/09/2019 | 177,01 | 179,55 | 175,58 | 178,12 | +1,12% | 2,24% | 1.719.400 |
| 19/09/2019 | 174,48 | 176,70 | 173,60 | 176,14 | +0,93% | 1,78% | 773.500 |
| 18/09/2019 | 176,01 | 176,50 | 171,96 | 174,52 | -0,84% | 2,58% | 1.172.700 |
| 17/09/2019 | 173,02 | 177,82 | 173,02 | 176,00 | -0,87% | 2,77% | 1.157.200 |
| 16/09/2019 | 173,89 | 178,09 | 173,13 | 177,55 | +1,49% | 2,85% | 959.000 |
| 13/09/2019 | 173,16 | 175,79 | 172,45 | 174,94 | +1,44% | 1,93% | 1.216.300 |
| 12/09/2019 | 174,39 | 175,45 | 172,00 | 172,45 | -0,38% | 1,98% | 874.500 |
| 11/09/2019 | 171,19 | 173,61 | 170,90 | 173,11 | +1,23% | 1,58% | 1.190.800 |
| 10/09/2019 | 174,03 | 174,14 | 166,65 | 171,01 | -2,17% | 4,30% | 1.849.400 |
| 09/09/2019 | 181,09 | 181,28 | 174,45 | 174,81 | -3,60% | 3,77% | 1.177.000 |